Page 1

option care health Exhibit 99.1 OPTION CARE HEALTH ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31 , 2021 BANNOCKBURN , IL . , May 6 , 2021 - Option Care Health , Inc. ( the “ Company ” or “ Option Care Health ” ) ( Nasdaq : OPCH ) , the nation's largest independent provider of home and alternate site infusion services , announced today financial results for the first quarter ended March 31 , 2021 . First Quarter 2021 Financial Highlights • Net revenue of $ 759.2 million , up 7.6 % compared to $ 705.4 million in the first quarter of 2020 • • • • • Gross profit of $ 165.5 million , or 21.8 % of net revenue , up 4.7 % compared to $ 158.0 million , or 22.4 % of revenue , in the first quarter of 2020 Net loss of $ 2.9 million , or $ 0.02 loss per share , compared to net loss of $ 19.9 million , or $ 0.11 loss per share , in the first quarter of 2020 Adjusted EBITDA of $ 52.2 million , up 30.0 % compared to $ 40.2 million in the first quarter of 2020 Cash flow from operations of $ 18.4 million compared to a cash flow of $ 18.4 million in the first quarter of 2020 Cash balances of $ 109.4 million at the end of the first quarter and no outstanding borrowings on the Company's $ 175.0 million revolver Additional Highlights • • • • Retired all outstanding second lien debt with incremental first lien debt under the Company's existing credit agreement ; recorded a debt extinguishment charge of $ 12.4 million in conjunction with the refinancing Launched Amondys 45 ™ ( casimersen ) , for the treatment of Duchenne muscular dystrophy in patients who have a confirmed mutation , and Uplizna® , for the treatment of neuromyelitis optica spectrum disorder Commenced operations at the Company's new , state of the art Care Management Center and Chronic Center of Excellence in Chicago , Illinois Subsequent to the end of the first quarter , acquired certain chronic therapy infusion assets from BioCureRx for $ 18.5 million John C. Rademacher , Chief Executive Officer , commented , “ The Option Care Health team delivered solid financial results in the first quarter while continuing to lay the foundation for sustained growth . We continue to make progress in integration efforts and invest in technology and clinical capabilities to further solidify our industry leading position . ”